SUZETE CLEUSA FERREIRA SPINA LOMBARDI
Projetos de Pesquisa
Unidades Organizacionais
LIM/05 - Laboratório de Poluição Atmosférica Experimental, Hospital das Clínicas, Faculdade de Medicina
LIM/31 - Laboratório de Genética e Hematologia Molecular, Hospital das Clínicas, Faculdade de Medicina
LIM/31 - Laboratório de Genética e Hematologia Molecular, Hospital das Clínicas, Faculdade de Medicina
3 resultados
Resultados de Busca
Agora exibindo 1 - 3 de 3
- SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study(2022) PRETE JR., Carlos A.; BUSS, Lewis F.; WHITTAKER, Charles; SALOMON, Tassila; OIKAWA, Marcio K.; PEREIRA, Rafael H. M.; MOURA, Isabel C. G.; DELERINO, Lucas; BARRAL-NETTO, Manoel; TAVARES, Natalia M.; FRANCA, Rafael F. O.; BOAVENTURA, Viviane S.; MIYAJIMA, Fabio; MENDRONE-JUNIOR, Alfredo; ALMEIDA-NETO, Cesar De; SALLES, Nanci A.; FERREIRA, Suzete C.; FLADZINSKI, Karine A.; SOUZA, Luana M. de; SCHIER, Luciane K.; INOUE, Patricia M.; XABREGAS, Lilyane A.; CRISPIM, Myuki A. E.; FRAIJI, Nelson; V, Fernando L. Araujo; CARLOS, Luciana M. B.; PESSOA, Veridiana; RIBEIRO, Maisa A.; SOUZA, Rosenvaldo E. de; SILVA, Sonia M. N. da; CAVALCANTE, Anna F.; VALENCA, Maria I. B.; V, Maria da Silva; LOPES, Esther; FILHO, Luiz A.; MATEOS, Sheila O. G.; NUNES, Gabrielle T.; SILVA-JUNIOR, Alexander L.; BUSCH, Michael P.; CASTRO, Marcia C.; DYE, Christopher; RATMANN, Oliver; FARIA, Nuno R.; NASCIMENTO, Vitor H.; SABINO, Ester C.Background: The COVID-19 situation in Brazil is complex due to large differences in the shape and size of regional epidemics. Understanding these patterns is crucial to understand future outbreaks of SARS-CoV-2 or other respiratory pathogens in the country. Methods: We tested 97,950 blood donation samples for IgG antibodies from March 2020 to March 2021 in 8 of Brazil's most populous cities. Residential postal codes were used to obtain representative samples. Weekly age- and sex-specific seroprevalence were estimated by correcting the crude seroprevalence by test sensitivity, specificity, and antibody waning. Results: The inferred attack rate of SARS-CoV-2 in December 2020, before the Gamma variant of concern (VOC) was dominant, ranged from 19.3% (95% credible interval [CrI] 17.5-21.2%) in Curitiba to 75.0% (95% CrI 70.8-80.3%) in Manaus. Seroprevalence was consistently smaller in women and donors older than 55 years. The age-specific infection fatality rate (IFR) differed between cities and consistently increased with age. The infection hospitalisation rate increased significantly during the Gamma-dominated second wave in Manaus, suggesting increased morbidity of the Gamma VOC compared to previous variants circulating in Manaus. The higher disease penetrance associated with the health system's collapse increased the overall IFR by a minimum factor of 2.91 (95% CrI 2.43-3.53). Conclusions: These results highlight the utility of blood donor serosurveillance to track epidemic maturity and demonstrate demographic and spatial heterogeneity in SARS-CoV-2 spread.
- Improved detection of hepatitis C virus-positive blood donors and determination of infection status(2023) NISHIYA, Anna S.; ALMEIDA-NETO, Cesar de; WITKIN, Steven S.; FERREIRA, Suzete C.; SALLES, Nanci A.; NOGUEIRA, Fatima A. H.; OLIVEIRA, Claudia Di Lorenzo; ROCHA, Vanderson; MENDRONE JUNIOR, AlfredoBackground In low-risk populations, variability in the sensitivity of current serological tests for Hepatitis C virus (HCV) blood donor screening may lead to the presence of false-positive results. This contributes to the unnecessary loss of blood donor samples as well as to difficulty in accurate donor counselling. The present study determined the optimal cut-off value of a chemiluminescent immunoassay for identification of HCV-reactive blood donors. Study Design and Methods In a retrospective cross-sectional analysis of 193 973 blood donations, 578 samples that were positive for HCV antibody in a chemiluminescent immunoassay and/or RNA screening tests were identified. Blood from 379 of these positive samples was available for retesting by a second confirmatory HCV immunoassay followed by a receiver operating characteristic (ROC) curve analysis. Donors were also recalled for a new analysis. Results Only 71 (18.7%) blood samples remained HCV-positive upon retesting, while 233 (61.5%) now tested negative and 75 (19.8%) yielding indeterminate results. A signal to cutoff ratio >= 4.32 was determined as the best differential threshold between a positive and negative result, increasing the positive predictive value from 27.3% to 66.7%. Conclusion Using a higher threshold for an HCV-positive blood sample enhances the chemiluminescent immunoassay screening test ' s accuracy and helps to improve donor counselling and notification processes.
- Detection of unreported usage of the antiretroviral drug lamivudine in two blood donors(2023) NISHIYA, Anna; SALLES, Nanci; ALMEIDA-NETO, Cesar de; FERREIRA, Suzete; NOGUEIRA, Fatima; ROCHA, Vanderson; MENDRONE, AlfredoBackground Unreported HIV antiretroviral (ARV) drug usage by blood donors compromises the ability to detect evidence of HIV infection in blood screening tests and represents a risk for blood transfusion safety. Our objective was to determine the frequency of undeclared ARV drug use by blood donors with altered HIV markers.Study Design and Methods This was a retrospective cross-sectional analysis of donations that were tested for HIV antibody (ab), antigen (ag), and RNA by chemiluminescent immunoassay and nucleic acid screening tests. Positive samples were retested and were subjected to ARV drug testing by high-performance liquid chromatography-tandem mass spectrometry.Results Of 345,252 blood donations, 361 (0.1%) were positive on initial testing. Samples from 296 (81.9%) of these donations were available for further analysis. The presence of HIV ab/ag and/or RNA was confirmed in 83 (28.0%) of these samples. All 296 bloods were subjected to ARV testing. The ARV drug lamivudine, at 11.3 and 6.7 ng/mL, was detected in 2 of 83 (2.4%) donations that were HIV positive. Other drugs were not detected.Conclusion Unreported ARV usage was identified in two candidates for blood donation. More intensive efforts to educate donors about disclosure and to investigate the extent of this phenomenon in Brazil are needed.